A 51-year-old woman was referred for evaluation of progressive dyspnea of 3 months' duration. She had received 3 doses of adalimumab for treatment of rheumatoid arthritis prior to the onset of her dyspnea. Her chest examination revealed absent diaphragmatic movement with inspiration. Spirometry showed a severe restrictive defect. Radiologic studies confirmed the diagnosis of bilateral diaphragmatic paralysis. Laboratory and radiologic workup excluded other possible causes of the diagnosis. Adalimumab was discontinued, and she was treated with bilevel positive airway pressure ventilation and intravenous immunoglobulin. Three months later, the diaphragmatic paralysis persisted. This is the second reported case of bilateral diaphragmatic paralysis occurring in a patient who had received adalimumab. Acute neuropathies are rare side effects of tumor necrosis factor-alpha inhibitors.
T umor necrosis factor alpha (TNF-α) inhibitors currently play a major role in the management of several autoimmune diseases. Infl iximab was the fi rst agent to be approved by the Food and Drug Administration (FDA) in 1998. TNF-α blockers are approved for the management of moderate to severely active rheumatoid arthritis or psoriatic arthritis, active ankylosing spondylitis, moderate to severely active Crohn's disease, and active ulcerative colitis in patients with an inadequate response to conventional therapy (1) . Five anti-TNF agents have been approved by the FDA: infl iximab, adalimumab, etanercept, golimumab, and certolizumab. Th ese agents have demonstrated acceptable safety and tolerability profi les. As with all immunosuppressants and immunomodulating therapies, TNF inhibitors increase the risk of infections. Several autoimmune adverse events have been reported, ranging from asymptomatic immunological alterations to life-threatening autoimmune diseases (2) . We report a case of bilateral diaphragmatic paralysis that occurred following the institution of adalimumab.
CASE PRESENTATION
A 51-year-old white woman was referred to Baylor University Medical Center at Dallas for an evaluation of dyspnea. Approximately 3 months prior to her referral, she experienced dyspnea and pleuritic chest pain and was seen in a local emergency department, where she was prescribed a short course of corticosteroids. One year prior to her symptoms, she was diagnosed with rheumatoid arthritis with symptoms of morning stiff ness and pain in the metacarpal and shoulder joints. She was initially treated with prednisone, methotrexate, and sulfasalazine. However, she failed to respond, and adalimumab was instituted. After three doses of adalimumab, she began to experience progressive dyspnea and marked orthopnea. She had no previous history of any respiratory symptoms and no other signifi cant medical history. She denied cough, chest pain, or lower extremity swelling. On examination, she was tachypneic and using her sternocleidomastoid and scalene muscles. Her chest examination revealed dullness to percussion in both bases, paradoxical inward movement of the abdominal wall, and poor diaphragmatic movement with inspiration. Her jugular veins were not distended, and there was no leg edema. Her heart sounds were normal. Neurologic examination disclosed no abnormalities.
A chest radiograph showed small lung volumes and a normal cardiac silhouette. Her computed tomography scan did not reveal any signifi cant pleural, parenchymal, or mediastinal abnormalities. Spirometry revealed a forced vital capacity (FVC) of 0.39 L (12% of predicted), forced expiratory volume in 1 second (FEV1) of 0.38 L (14% of predicted), and FEV1/FVC of 97%, consistent with a severe restrictive defect. Respiratory muscle force testing showed a negative inspiratory force of -14 (17% of predicted) and an expiratory force of +24 (16% of predicted). A fl uoroscopy sniff test confi rmed the diagnosis of bilateral diaphragmatic paralysis. Her laboratory workup did not reveal any fi ndings associated with the known causes of diaphragmatic paralysis, as shown in the Table. Adalimumab was stopped, and she was empirically started on monthly intravenous immunoglobulin infusions. Bilevel positive airway pressure was instituted to be used at night, and intermittent positive pressure ventilation with a 40 cm pressure limit was prescribed to assist with chest wall expansion. Th ree months later, she continued to show diaphragmatic paralysis but was less dyspneic.
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DISCUSSION
Demyelinating neuropathies have been reported as rare adverse events with anti-TNF-α therapy. Th e reported culprit has more often been infl iximab than etanercept or adalimumab. Acute or chronic demyelinating neuropathies may occur a few months after the institution of TNF-α treatment, very often associated with conduction blocks on nerve conduction studies. However, discontinuation of the off ending drug and treatment for demyelinating neuropathies have been associated with improvement in the neuropathy (3) (4) (5) .
Th e proposed pathogeneses of TNF-α-blocker-associated neuropathies include both a T-cell and humoral immune attack against peripheral nerve myelin and inhibition of vital axonal signaling functions. Vasculitis-induced nerve ischemia, either from the underlying condition or enhanced by the drugs, remains a possibility in some cases. Neuromuscular biopsies in several patients, especially with mononeuritis simplex or multiplex, have revealed necrotizing vasculitis (6) . Th e temporal relationship between initiation of TNF-α antagonist therapy and the onset or progression of vasculitis suggests that TNF-α inhibition triggers or exacerbates vessel infl ammation (6) . Proposed mechanisms whereby TNF-α inhibitors promote vasculitis include 1) development of antidrug or autoantibodies during TNF-α blockade that form immune complexes that deposit in the walls of small blood vessels to activate complement and trigger a type III hypersensitivity reaction; 2) changes in T-cell cytokine production; 3) elevation of nuclear antigen levels in the blood because of increased apoptosis of cells targeted by TNF-α inhibitors; and 4) an increase in the immunogenic load related to downregulation of C-reactive protein by TNF-α inhibitors (7, 8) .
Adalimumab (Humira; Abbott, Abbott Park, IL) is a recombinant human IgG1 monoclonal antibody specifi c for human TNF-α. Th e drug was developed using phage display technology resulting in an antibody with human-derived heavy-and light-chain variable regions and human IgG-1 constant regions. Adalimumab binds specifi cally with TNF-α, blocking its interaction with the p55 and p75 cell surface TNF receptors and thereby modulating TNF-induced or -modulated biological responses.
Neurologic defi cits seen in patients who are receiving adalimumab include Guillain-Barré syndrome (9), wrist drop (10), progressive sensory demyelinating polyneuropathy (11) , and optic neuropathy (12) (13) (14) . Alexopoulou et al reported the other case of acute bilateral phrenic neuropathy following treatment with adalimumab (15) . Th is patient was treated with adalimumab for psoriasis and developed acute bilateral phrenic neuropathy after the fourth dose. She was treated with oxygen, and her symptoms resolved 4 weeks following the discontinuation of adalimumab. Th is is the second reported case of diaphragmatic paralysis in association with adalimumab use. In this case, the temporal association of the phrenic nerve paralysis with the administration of adalimumab and the absence of any other known trigger suggest adalimumab to be the culprit agent for this condition. Th e patient had no evidence of other causes of mononeuropathies, including diabetes mellitus, amyloidosis, infections (e.g., HIV), malignancy, myasthenia gravis, and amyotrophic lateral sclerosis. Although monofocal motor neuropathy with conduction block and electrophysiological evidence of demyelinating neuropathy might be a rare side eff ect of adalimumab and other TNF-α blockers, these agents should be considered in the diff erential diagnoses of these neuropathies.
